Rocket One (RKTO) risk factors

54 risks, 1 new, 2 dropped, 5 reworded since the prior year. Auditors issued a going concern warning following net losses of $12.5 million in 2025 and an accumulated deficit of $72.9 million. Financial restatement risks were dropped. Disclosures on orphan drug designation for product candidate HT-KIT and accumulated deficits were updated.

55 risks. The company faces standard clinical-stage biopharmaceutical risks, dominated by heavy reliance on third-party manufacturers, unpredictable FDA approval timelines, and ongoing capital needs.